QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.
Follow QGEN
QIAGEN N.V. (QGEN) Altman Z-score
QIAGEN N.V.'s Altman Z-score for fiscal 2025 is 3.81, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.81 | (0.19) |
| FY2024 | 4.00 | 0.16 |
| FY2023 | 3.84 | 0.17 |
| FY2022 | 3.67 | 0.14 |
| FY2021 | 3.53 | 0.29 |
| FY2020 | 3.25 | 0.94 |
| FY2019 | 2.31 | (0.08) |
| FY2018 | 2.39 | (0.22) |
| FY2017 | 2.61 | (0.62) |
| FY2016 | 3.23 | (0.13) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.24 | — | 0.28 | |
| Retained earnings / total assets | 0.44 | — | 0.61 | |
| EBIT / total assets | 0.07 | — | 0.24 | |
| Market value of equity / total liabilities | 3.90 | — | 2.34 | |
| Sales / total assets | 0.33 | — | 0.33 | |
| Altman Z-score | Safe zone | 3.81 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 5.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 8.0× |
| QGEN QIAGEN N.V. | 3.8× |
| TWST Twist Bioscience Corporation compare | 3.4× |
| RVTY Revvity Inc. compare | 2.5× |
| CRL Charles River Laboratories International, Inc. compare | 2.4× |
| RDNT RadNet, Inc. compare | 2.0× |
| ICLR ICON PLC compare | 2.0× |
| SHC Sotera Health Company compare | 1.8× |
| GRAL GRAIL, Inc. compare | 0.4× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets